New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels Read more about New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions Read more about bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress Read more about bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row Read more about bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row
bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition Read more about bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
bluebird bio: Transforming the Treatment of Sickle Cell Disease Read more about bluebird bio: Transforming the Treatment of Sickle Cell Disease
bluebird bio Completes Planned Business Separation Read more about bluebird bio Completes Planned Business Separation
Najoh Tita-Reid Member of the Compensation CommitteeMember of the Nominating and Corporate Governance Committee Najoh Tita-Reid Director